Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Muhammad Abdul-Ghani

Showing results (31-40 of 98) with videos related to

Pageof 10
Sort By:
Diabetes, Obesity & Metabolism|December 12, 2017
Insulin secretion predicts the response to therapy with exenatide plus pioglitazone, but not to basal/bolus insulin in poorly controlled T2DM patients: Results from the Qatar studyMuhammad Abdul-Ghani, Osama Migahid, Ayman Megahed, et al.
Diabetes, Obesity & Metabolism|December 22, 2023
The impact of increased hepatic glucose production caused by empagliflozin on plasma glucose concentration in individuals with type 2 diabetes and nondiabetic individualsSiham Abdelgani, Ahmed Khattab, John Adams, et al.
Surgery for Obesity and Related Diseases : Official Journal of the American Society for Bariatric Surgery|February 1, 2016
Diverted sleeve gastrectomy with ileal transposition in overweight, obese, and morbidly obese patients with type 2 diabetes: results of 1-year follow-upAlper Celik, Eylem Cagiltay, Surendra Ugale, et al.
Diabetes, Obesity & Metabolism|September 28, 2018
Pioglitazone prevents the increase in plasma ketone concentration associated with dapagliflozin in insulin-treated T2DM patients: Results from the Qatar StudyMuhammad Abdul-Ghani, Osama Migahid, Ayman Megahed, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|February 27, 2026
Personal Viewpoint: Risk stratification and counseling of living kidney donor candidates with prediabetesKatafan Achkar, Fawaz Al Ammary, Muhammad Abdul-Ghani, et al.
Diabetes Care|July 17, 2020
Newly Discovered Abnormal Glucose Tolerance in Patients With Acute Myocardial Infarction and Cardiovascular Outcomes: A Meta-analysisNitchakarn Laichuthai, Muhammad Abdul-Ghani, Mikhail Kosiborod, et al.
Diabetes Care|May 27, 2026
Renal Lipotoxicity: Mechanisms and Therapeutic PerspectivesHussein Zaitoon, Eugene Feigin, Muhammad Abdul-Ghani, et al.
Diabetes Care|November 15, 2007
Decreased non-insulin-dependent glucose clearance contributes to the rise in fasting plasma glucose in the nondiabetic rangeRucha Jani, Marjorie Molina, Masafumi Matsuda, et al.
Diabetes|June 15, 2017
Inhibition of Renal Sodium-Glucose Cotransport With Empagliflozin Lowers Fasting Plasma Glucose and Improves β-Cell Function in Subjects With Impaired Fasting GlucoseMuhammad Abdul-Ghani, Hussein Al Jobori, Giuseppe Daniele, et al.
Diabetes, Obesity & Metabolism|January 28, 2017
Determinants of the increase in ketone concentration during SGLT2 inhibition in NGT, IFG and T2DM patientsHussein Al Jobori, Giuseppe Daniele, John Adams, et al.
Pageof 10

Showing results (31-40 of 98) with videos related to

Sort By:
Pageof 10
Diabetes, Obesity & Metabolism|December 12, 2017
Insulin secretion predicts the response to therapy with exenatide plus pioglitazone, but not to basal/bolus insulin in poorly controlled T2DM patients: Results from the Qatar studyMuhammad Abdul-Ghani, Osama Migahid, Ayman Megahed, et al.
Diabetes, Obesity & Metabolism|December 22, 2023
The impact of increased hepatic glucose production caused by empagliflozin on plasma glucose concentration in individuals with type 2 diabetes and nondiabetic individualsSiham Abdelgani, Ahmed Khattab, John Adams, et al.
Surgery for Obesity and Related Diseases : Official Journal of the American Society for Bariatric Surgery|February 1, 2016
Diverted sleeve gastrectomy with ileal transposition in overweight, obese, and morbidly obese patients with type 2 diabetes: results of 1-year follow-upAlper Celik, Eylem Cagiltay, Surendra Ugale, et al.
Diabetes, Obesity & Metabolism|September 28, 2018
Pioglitazone prevents the increase in plasma ketone concentration associated with dapagliflozin in insulin-treated T2DM patients: Results from the Qatar StudyMuhammad Abdul-Ghani, Osama Migahid, Ayman Megahed, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|February 27, 2026
Personal Viewpoint: Risk stratification and counseling of living kidney donor candidates with prediabetesKatafan Achkar, Fawaz Al Ammary, Muhammad Abdul-Ghani, et al.
Diabetes Care|July 17, 2020
Newly Discovered Abnormal Glucose Tolerance in Patients With Acute Myocardial Infarction and Cardiovascular Outcomes: A Meta-analysisNitchakarn Laichuthai, Muhammad Abdul-Ghani, Mikhail Kosiborod, et al.
Diabetes Care|May 27, 2026
Renal Lipotoxicity: Mechanisms and Therapeutic PerspectivesHussein Zaitoon, Eugene Feigin, Muhammad Abdul-Ghani, et al.
Diabetes Care|November 15, 2007
Decreased non-insulin-dependent glucose clearance contributes to the rise in fasting plasma glucose in the nondiabetic rangeRucha Jani, Marjorie Molina, Masafumi Matsuda, et al.
Diabetes|June 15, 2017
Inhibition of Renal Sodium-Glucose Cotransport With Empagliflozin Lowers Fasting Plasma Glucose and Improves β-Cell Function in Subjects With Impaired Fasting GlucoseMuhammad Abdul-Ghani, Hussein Al Jobori, Giuseppe Daniele, et al.
Diabetes, Obesity & Metabolism|January 28, 2017
Determinants of the increase in ketone concentration during SGLT2 inhibition in NGT, IFG and T2DM patientsHussein Al Jobori, Giuseppe Daniele, John Adams, et al.
Pageof 10